• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
XU Hongjiang, SHI Wei, SONG Wei, ZHANG Ying, ZHAO Kaidi, ZHANG Yinsheng, YANG Ling, WANG Jinan. Pharmacodynamic study of magnesium isoglycyrrhizinate in HBV transgenic mouse model[J]. Journal of China Pharmaceutical University, 2019, 50(4): 475-480. DOI: 10.11665/j.issn.1000-5048.20190413
Citation: XU Hongjiang, SHI Wei, SONG Wei, ZHANG Ying, ZHAO Kaidi, ZHANG Yinsheng, YANG Ling, WANG Jinan. Pharmacodynamic study of magnesium isoglycyrrhizinate in HBV transgenic mouse model[J]. Journal of China Pharmaceutical University, 2019, 50(4): 475-480. DOI: 10.11665/j.issn.1000-5048.20190413
shu

Pharmacodynamic study of magnesium isoglycyrrhizinate in HBV transgenic mouse model

More Information
    Graphical Abstract
    • Abstract
  • This study aims to discuss the therapeutic effect of magnesium isoglycyrrhizinate on hepatitis B virus(HBV)transgenic mouse and its effect on cellular immunity and liver inflammation. The changes of serum aspartate aminotransferase(AST)and alanine aminotransferase(ALT)activity, the difference of serum hepatitis B surface antigen(HBsAg), liver tissue HBsAg mRNA, and the pathological morphological changes of liver tissue were detected to investigate the hepatic inflammatory lesions and the efficacy of magnesium isoglycyrrhizinate in HBV transgenic mouse. Peripheral blood lymphocytes were classified by flow cytometry, and serum cytokines were detected by cytometric bead array(CBA)to explore the mechanism of magnesium isoglycyrrhizinate to reduce hepatic inflammatory lesions in HBV transgenic mouse. After grouping HBV transgenic mouse with serum transaminase activity and 35 days of continuous administration, serum transaminases level in magnesium isoglycyrrhizinate ［15 mg/(kg ·d)］ group was significantly lower than that in control group(P< 0. 05), serum HBsAg protein and liver tissue HBsAg mRNA increased with time, but there was no significant difference between the two groups. The main pathological changes of liver were liver cell swelling, necrosis and focal inflammatory cell infiltration, and the pathological changes of liver in magnesium isoglycyrrhizinate group were lighter than those in control group. The number of CD8+ cells in the blood of magnesium isoglycyrrhizinate group was significantly less than that in the control group(P< 0. 05)and the CD4+/CD8+ cell ratio was significantly higher than that in the control group(P< 0. 05). The content of inflammatory cytokines in serum of magnesium isoglycyrrhizinate group decreased significantly(P< 0. 05). Magnesium isoglycyrrhizinate can regulate the immune function of HBV transgenic mouse, decrease the infiltration of inflammatory cells in hepatic tissue and hepatocyte injury, but do not affect the expression of hepatocyte HBsAg.
    • FullText(HTML)
    • References (14)
  • [1]
    Xie C,Li X,Zhu J,et al.Magnesium isoglycyrrhizinate suppresses LPS-induced inflammation and oxidative stress through inhibiting NF-κB and MAPK pathways in RAW264.7 cells[J].Bioorg Med Chem,2019,27(3):516-524.
    [2]
    Ma D,Zhang J,Zhang Y,et al.Inhibition of myocardial hypertrophy by magnesium isoglycyrrhizinate through the TLR4/NF-κB signaling pathway in mice[J].Int Immunopharmacol,2018,55:237-244.
    [3]
    Ou MH.Pharmacology and clinical research progress of magnesium isoglycyrrhizinate[J].China Pharm(中国药业),2010,19(15):83-85.
    [4]
    Guo WN,Zhu B,Ai L,et al.Animal models for the study of hepatitis B virus infection[J].Zool Res,2018,39(1):25-31.
    [5]
    Dupinay T,Gheit T,Roques P,et al.Discovery of naturally occurring transmissible chronic hepatitis B virus infection among Macaca fascicularis from Mauritius Island[J].Hepatol,2013,58(5):1610-1620.
    [6]
    Dandri M,Volz TK,Lütgehetmann M,et al.Animal models for the study of HBV replication and its variants[J].J Clin Virol,2005,34(Suppl 1):S54-S62.
    [7]
    Chisari FV,Pinkert CA,Milich DR,et al.A transgenic mouse model of the chronic hepatitis B surface antigen carrier state[J].Science,1985,230(4730):1157-1160.
    [8]
    Babinet C,Farza H,Morello D,et al.Specific expression of hepatitis B surface antigen(HBsAg)in transgenic mouse[J].Science,1985,230(4730):1160-1163.
    [9]
    Guidotti L G,Matzke B,Schaller H,et al.High-level hepatitis B virus replication in transgenic mouse[J].J Virol,1995,69(10):6158-6169.
    [10]
    Kang AJ,Dong YH,Tian F,et al.Pathologic observation on C57BL/6J-HBV transgenic mouse[J].Chin J Lab Anim Sci(中国实验动物学杂志),2002,12(1):8-10.
    [11]
    Huang LR,Wu HL,Chen PJ,et al.An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection[J].Proc Natl Acad Sci,2006,103(47):17862-17867.
    [12]
    Huang YH,Fang CC,Tsuneyama K,et al.A murine model of hepatitis B-associated hepatocellular carcinoma generated by adeno-associated virus-mediated gene delivery[J].Int J Oncol,2011,39(6):1511-1519.
    [13]
    Dembek C,Protzer U.Mouse models for therapeutic vaccination against hepatitis B virus[J].Med Microbiol Immunol,2015,204(1):95-102.
    [14]
    Zheng DM,Guo YH,Zheng F.Flow cytometry analysis of intrahepatic lymphocyte subsets in chronic hepatitis B[J].J Mod Med Health(现代医药卫生),2012,28(1):102-104.
    • Related Articles

  • Related Articles

    [1]CHEN Feihong, ZHAO Deming, GOU Shaohua. Research progress on the antitumor effects of platinum-based chemo-immunotherapies[J]. Journal of China Pharmaceutical University, 2024, 55(1): 26-35. DOI: 10.11665/j.issn.1000-5048.2023120201
    [2]XU Yungen. Advances in drug development based on immunoregulation[J]. Journal of China Pharmaceutical University, 2024, 55(1): 1-4. DOI: 10.11665/j.issn.1000-5048.2024022601
    [3]YU Dongmei, GUO Wei, LEI Wen, GE Yaoyao, CHEN Yucong, GAO Xiangdong, YAO Wenbing. Advances of lncRNA in immune cells and autoimmune diseases[J]. Journal of China Pharmaceutical University, 2017, 48(3): 371-376. DOI: 10.11665/j.issn.1000-5048.20170319
    [4]LIANG Xiao-qing, SHI Chen-yang, WANG Ke, HE Xin, LIU Si-guo, HUANG Xiao-feng, LIU Yu. Anti-angiogenesis and anti-tumor activity of the fully human anti-VEGF165 monoclonal antibody obtained from the five-feature transgenic mice[J]. Journal of China Pharmaceutical University, 2012, 43(6): 560-566.
    [5]Tumor microenvironment：A novel target for antitumor activity of polysaccharides[J]. Journal of China Pharmaceutical University, 2010, 41(1): 1-10.
    [8]Effects of Mixed Nucleotide on Acute Hepatic Injury and Immunoregulation in Mice[J]. Journal of China Pharmaceutical University, 2001, (6): 44-47.
    [9]Immunomodulating Activity of Yang Zheng He Ji[J]. Journal of China Pharmaceutical University, 1995, (1): 37-40.
    [10]The Immunoregulative Effect of the Synthetic Artifact of Royel Jelly Acid[J]. Journal of China Pharmaceutical University, 1991, (2): 117-118.

  • Cited by

    Periodical cited type(3)

    1. 曾雪亮，钟文敏，李蓓. 异甘草酸镁联合疗法治疗慢性乙型肝炎的效果及安全性的meta分析. 中国当代医药. 2021(30): 13-17 .
    2. 高华，何海妮，刘莉娜. 异甘草酸镁注射液对耐多药结核鼠T淋巴细胞亚群及血清抗体的影响. 临床和实验医学杂志. 2020(22): 2382-2385 .
    3. 柏杰. 双环醇联合异甘草酸镁治疗失代偿期肝硬化疗效观察. 智慧健康. 2020(31): 115-116 .

    Other cited types(1)

Catalog

    Get Citation
    PDF
    XML
    Article views (518) PDF downloads (772) Cited by(4)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：309719

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return